Nanotechnology Now - Press Release: "Advanced Magnetics, Inc. to Present at the Bank of America Health Care Conference"

Home > Press > Advanced Magnetics, Inc. to Present at the Bank of America Health Care Conference

Abstract:
Advanced Magnetics, Inc. (Nasdaq: AMAG) today announced that it will participate in the Bank of
America Health Care Conference being held May 30-June 1, 2007 at the Four Seasons Hotel in Las Vegas, NV. Brian J.G. Pereira, MD, President and CEO of Advanced Magnetics, will present an overview of the company on Wednesday, May 30, at 3:20 pm PDT.

Advanced Magnetics, Inc. to Present at the Bank of America Health Care Conference

Cambridge, MA | Posted on May 24th, 2007

A live webcast of this presentation will be accessible through the
Investors section of the company's website at http://www.advancedmagnetics.com .
Following the conference, the webcast will be archived on the Advanced
Magnetics website until June 15, 2007.

####

About Advanced Magnetics, Inc.
Advanced Magnetics, Inc. is a biopharmaceutical company that utilizes
its proprietary nanoparticle technology for the development and
commercialization of therapeutic iron compounds to treat anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease.

Ferumoxytol, the company's key product candidate, is being developed
for use as an intravenous iron replacement therapeutic for the treatment of
iron deficiency anemia in chronic kidney disease. The company has completed
enrollment in four Phase III clinical trials with ferumoxytol and has
presented data on three of the four trials.

Combidex, the company's other product under development, is an
investigational functional molecular imaging agent consisting of iron oxide
nanoparticles for use in conjunction with magnetic resonance imaging (MRI)
to aid in the differentiation of cancerous from normal lymph nodes. In
March 2005, the company received an approvable letter from the FDA with
respect to Combidex, subject to certain conditions.

The company has two commercial products, Feridex I.V.(R) and
GastroMARK(R), both of which are imaging agents that are approved and
marketed in the United States, Europe and other countries.